Key facts
- Envisagenics’s last known valuation is $150.0M.
- It has raised $40.5M across 2 recorded rounds; the latest was Early Stage VC ($19.2M) in Sep 2021.
- Notable investors include SV Angel, National Institutes of Health, M12, Madrona Venture Group, Hawktail — 24 tracked in total.
- Envisagenics has filed 3 Form Ds with the SEC since 2017, most recently Oct 2021 ($19.2M sold to 24 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for Envisagenics
Funding rounds
2 roundsAbout Envisagenics
Developer of a bioinformatics platform designed to accelerate the development of novel therapeutics. The company's platform incorporates advanced artificial intelligence and machine learning algorithms to analyze, predict, and interpret transcriptomic data, enabling researchers to identify and validate potential drug targets.
- Sector
- Healthcare
- HQ
- Long Island City, NY, United States
- Founded
- 2014
- Employees
- 49
- Website
- envisagenics.com/
- Ownership
- Privately Held (backing)
Envisagenics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Envisagenics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Envisagenics in its N-PORT filings yet. We sweep new filings monthly.